About castle biosciences inc - CSTL
Castle Biosciences, Inc. is a molecular diagnostics company, which offers innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
CSTL At a Glance
Castle Biosciences, Inc.
1500 West Parkwood Avenue
Friendswood, Texas 77546
| Phone | 1-866-788-9007 | Revenue | 344.23M | |
| Industry | Medical Specialties | Net Income | -24,158,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 3.662% | |
| Fiscal Year-end | 12 / 2026 | Employees | 883 | |
| View SEC Filings |
CSTL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.276 |
| Price to Book Ratio | 2.452 |
| Price to Cash Flow Ratio | 17.52 |
| Enterprise Value to EBITDA | -424.26 |
| Enterprise Value to Sales | 2.513 |
| Total Debt to Enterprise Value | 0.043 |
CSTL Efficiency
| Revenue/Employee | 389,840.317 |
| Income Per Employee | -27,359.003 |
| Receivables Turnover | 7.935 |
| Total Asset Turnover | 0.592 |
CSTL Liquidity
| Current Ratio | 5.258 |
| Quick Ratio | 5.109 |
| Cash Ratio | 4.361 |
CSTL Profitability
| Gross Margin | 68.66 |
| Operating Margin | -12.436 |
| Pretax Margin | -8.574 |
| Net Margin | -7.018 |
| Return on Assets | -4.154 |
| Return on Equity | -5.214 |
| Return on Total Capital | -4.757 |
| Return on Invested Capital | -4.899 |
CSTL Capital Structure
| Total Debt to Total Equity | 7.861 |
| Total Debt to Total Capital | 7.288 |
| Total Debt to Total Assets | 6.076 |
| Long-Term Debt to Equity | 7.469 |
| Long-Term Debt to Total Capital | 6.925 |